Stone Adam Leo

SEC source: 0001727440-26-000003 · form4-07222026_110718.xml · derivative · entry 2

Stone Adam Leo · CIK 0001727440 · Former Dir, Ofc, 10% Ownr

10b5-1 filing: No plan indicated

Ownership: Indirect · By Perceptive Capital Solutions Holdings

Disclosed balance after: 0

Underlying: Common Stock · 2,066,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis.

F1 · price: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis.

F1 · derivative.exercise_date: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis.

F1 · derivative.expiration_date: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis.

F2 · ownership.nature: The securities reported herein are held by Perceptive Capital Solutions Holdings (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.

SEC source: 0001727440-26-000003 · form4-07222026_110718.xml · nonDerivative · entry 1

Stone Adam Leo · CIK 0001727440 · Former Dir, Ofc, 10% Ownr

10b5-1 filing: No plan indicated

Ownership: Indirect · By Perceptive Capital Solutions Holdings

Disclosed balance after: 2,352,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis.

F2 · ownership.nature: The securities reported herein are held by Perceptive Capital Solutions Holdings (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.

SEC source: 0000950103-26-009251 · ownership.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,000

Underlying: Ordinary Shares · 48,000 shares

Expires 2036-06-15

F1 · derivative.exercise_date: These Options vest 100% on the first anniversary of the grant date, June 16, 2026.

SEC source: 0001193125-26-267489 · ownership.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2036-06-10

F1 · derivative.exercise_date: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001062993-25-011689 · form4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2035-06-12

F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001140361-24-042486 · form4.xml · nonDerivative · entry 1

ARYA Sciences Holdings IV · CIK 0001838903 · 10% owner

Stone Adam Leo · CIK 0001727440 · 10% owner

ALTMAN MICHAEL SETH · CIK 0001746738 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On September 27, 2024, ARYA Sciences Holdings IV (the "Sponsor") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the "Common Stock"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the "Issuer"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the "Earn-Out Shares"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the "Earn-Out Period") of the closing (the "Closing") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period.

F1 · price: On September 27, 2024, ARYA Sciences Holdings IV (the "Sponsor") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the "Common Stock"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the "Issuer"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the "Earn-Out Shares"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the "Earn-Out Period") of the closing (the "Closing") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period.

F2 · ownership.direct: The reported securities were directly held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman had voting and investment discretion with respect to any shares of Common Stock that were held of record by the Sponsor and may be deemed to have shared beneficial ownership of any shares of Common Stock that were held directly by the Sponsor.

SEC source: 0001140361-24-035180 · form4.xml · derivative · entry 3

Stone Adam Leo · CIK 0001727440 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARYA Sciences Holdings IV

Disclosed balance after: 0

Underlying: Class A ordinary shares · 2,647,500 shares

Expires not disclosed

F1 · derivative.exercise_price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis.

F2 · derivative.exercise_price: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period.

F1 · kind: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis.

F2 · kind: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period.

F1 · price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis.

F2 · price: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period.

F1 · derivative.exercise_date: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis.

F2 · derivative.exercise_date: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period.

F1 · derivative.expiration_date: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis.

F2 · derivative.expiration_date: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period.

F4 · ownership.nature: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Michael Altman and the Reporting Person. As such, Mr. Altman and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.

SEC source: 0001140361-24-035180 · form4.xml · derivative · entry 2

Stone Adam Leo · CIK 0001727440 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARYA Sciences Holdings IV

Disclosed balance after: 2,647,500

Underlying: Class A ordinary shares · 1,000,000 shares

Expires not disclosed

F3 · derivative.exercise_price: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration.

F3 · kind: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration.

F3 · price: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration.

F3 · derivative.exercise_date: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration.

F3 · derivative.expiration_date: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration.

F4 · ownership.nature: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Michael Altman and the Reporting Person. As such, Mr. Altman and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.

SEC source: 0001140361-24-035180 · form4.xml · nonDerivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARYA Sciences Holdings IV

Disclosed balance after: 0

F1 · kind: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis.

F2 · kind: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period.

F1 · price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis.

F2 · price: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period.

F4 · ownership.nature: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Michael Altman and the Reporting Person. As such, Mr. Altman and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.

SEC source: 0001140361-24-030027 · form4.xml · nonDerivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Perceptive Capital Solutions Holdings

Disclosed balance after: 286,250

F1 · kind: The reported Class A ordinary shares were purchased in a private placement by Perceptive Capital Solutions Holdings (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-279598).

F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.

SEC source: 0001062993-24-019353 · form4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,400

Underlying: Common Stock · 34,400 shares

Expires 2034-06-11

F1 · derivative.exercise_date: This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001062993-24-003729 · form4.xml · derivative · entry 3

Stone Adam Leo · CIK 0001727440 · Director · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 36,300 shares

Expires 2032-06-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-24-003729 · form4.xml · nonDerivative · entry 2

Stone Adam Leo · CIK 0001727440 · Director · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,082

SEC source: 0001062993-24-003729 · form4.xml · nonDerivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-23-013981 · form4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,300

Underlying: Ordinary Shares · 36,300 shares

Expires 2033-06-21

F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

SEC source: 0001062993-23-013156 · form4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,650

Underlying: Common Stock · 9,650 shares

Expires 2033-06-06

F1 · derivative.exercise_date: This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001062993-22-023965 · form4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,650

Underlying: Common Stock · 9,650 shares

Expires 2032-12-13

F1 · derivative.exercise_date: This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001062993-22-015489 · form4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,300

Underlying: Ordinary Shares · 36,300 shares

Expires 2032-06-23

F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

SEC source: 0001062993-22-014590 · form4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001140361-21-024478 · form4.xml · nonDerivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARYA Sciences Holdings V

Disclosed balance after: 499,000

F1 · kind: The reported Class A ordinary shares were purchased in a private placement by ARYA Sciences Holdings V (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-257335).

F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.

SEC source: 0001140361-21-006911 · form4.xml · nonDerivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARYA Sciences Holdings IV

Disclosed balance after: 499,000

F1 · kind: . The reported Class A ordinary shares were purchased in a private placement by ARYA Sciences Holdings IV (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333- 252960).

F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.

SEC source: 0001140361-20-018162 · form4.xml · nonDerivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARYA Sciences Holdings III

Disclosed balance after: 499,000

F1 · kind: The reported Class A ordinary shares were purchased as Private Placement Shares by ARYA Sciences Holdings III (the "Sponsor") for $10.00 per share, as described under the heading "Description of Securities " in the Issuer's registration statement on Form S-1 (File No. 333- 239986).

F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, the Reporting Person and Michael Altman. As such, the Reporting Person and Mr. Altman have voting and investment discretion with respect to the Class A ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class A ordinary shares held directly by the Sponsor.

SEC source: 0000899243-20-017154 · doc4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2020 and vests in full on the earlier to occur of June 16, 2021 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001140361-20-013461 · form4.xml · nonDerivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARYA Sciences Holdings II

Disclosed balance after: 499,000

F1 · kind: The reported Class A ordinary shares are within 499,000 of the Issuer's Private Placement Units, as described under the heading "Description of Securities " in the Issuer's registration statement on Form S-1 (File No. 333- 238488), purchased by the ARYA Sciences Holdings II (the "Sponsor") for $10.00 per Private Placement Unit.

F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, the Reporting Person and Michael Altman. As such, the Reporting Person and Mr. Altman have voting and investment discretion with respect to the Class A ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class A ordinary shares held directly by the Sponsor.

SEC source: 0000899243-19-017134 · doc4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-13

F1 · derivative.exercise_date: This option was granted on June 13, 2019 and vests in full on the earlier to occur of June 13, 2020 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001012975-18-001285 · edgar.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,165

Underlying: Common Stock · 8,165 shares

Expires 2028-12-13

F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001012975-18-000937 · edgar.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,835

Underlying: Common Stock · 1,835 shares

Expires 2028-07-25

F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.